This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Novo's Wegovy Pill Shows Weight Loss After Switching From Injections
by Zacks Equity Research
NVO's Wegovy pill delivers an average weight loss of 4.1% after three months for adults switching from injectable GLP-1 therapies.
NVOPositive Net Change LLYPositive Net Change ALDXNegative Net Change ACIUNegative Net Change
biotechnology biotechs medical pharmaceuticals
uniQure Plunges on Additional Data From Huntington's Disease Study
by Zacks Equity Research
QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty.
QURENegative Net Change ACIUNegative Net Change PGENNegative Net Change
biotechnology biotechs medical pharmaceuticals
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
by Sundeep Ganoria
MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.
MRNAPositive Net Change BNTXPositive Net Change PFENegative Net Change MRKNegative Net Change
biotechs immuno-therapy medical messenger-rna pharmaceuticals vaccines
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
by Kanishka Das
Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
IRWDPositive Net Change PGENNegative Net Change INONegative Net Change
biotechs medical
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
by Zacks Equity Research
Iovance hits a 52-week high after raising its 2026 revenue outlook to $410-$420 million on strong demand for its marketed therapies.
IOVANegative Net Change ACIUNegative Net Change PGENNegative Net Change
biotechs
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
by Ahan Chakraborty
NVO's latest Hengrui deal adds a phase I-ready, once-weekly oral GLP-1/GIP candidate, building on deals for oral drug-delivery tech and small-molecule approaches.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Summit Shares Jump on $2B Strategic Investment From AstraZeneca
by Zacks Equity Research
SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.
SMMTPositive Net Change AZNNegative Net Change PFENegative Net Change
biotechs medical pharmaceuticals
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo
by Zacks Equity Research
ABBV wins FDA approval for Juvmo, expanding its Parkinson's portfolio with a once-daily oral treatment and potential $5B-plus PD opportunity.
ABBVPositive Net Change ACIUNegative Net Change PGENNegative Net Change
biotechs medical pharmaceuticals
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
by Zacks Equity Research
MIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.
MIRMNegative Net Change REGNNegative Net Change PGENNegative Net Change
biotechs
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
by Zacks Equity Research
Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.
KROSPositive Net Change REGNNegative Net Change TAKNegative Net Change PGENNegative Net Change
biotechs